NASDAQ$ZNTL
Zentalis Pharmaceuticals Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Reported second quarter financial results and provided an operational update.
Zentalis Pharmaceuticals reported its Q2 2022 financial results, highlighting the strengthening of its leadership team, a $25 million equity investment from Pfizer, and approximately $200.2 million in gross proceeds from a recent follow-on offering, extending the company's cash runway into 2025. The company is focusing on advancing its lead clinical candidates, ZN-c3 and ZN-d5, while discontinuing the development of ZN-c5 and ZN-e4.
- Received a $25 million equity investment from Pfizer to jointly advance and expand clinical development of ZN-c3.
- Raised approximately $200.2 million in gross proceeds from a recent follow-on offering, extending cash runway into 2025.
- Appointed Kimberly Blackwell, M.D. as Chief Executive Officer.
- Focusing resources on investigating the full potential of ZN-c3 and ZN-d5, and discontinuing the clinical development of ZN-c5 and ZN-e4.
Headline financials
Revenue & EPS history
Zentalis · Revenue · Quarterly
$400K
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q2 2022
-1.4%
Avg return
Earnings day
-2.0%
Avg return
5 days after
+0.8%
Avg return
30 days after
60%
15 / 25 earnings
Positive
+14.5%
Q1 2023
Best reaction
-43.0%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +3.1% | -3.2% | — | |
| Q1 2026 | +3.9% | -1.7% | -15.0% | |
| Q3 2025 | +6.2% | +0.8% | +9.8% | |
| Q2 2025 | +5.1% | +2.2% | +26.8% | |
| Q1 2025 | -2.5% | +3.3% | +10.7% | |
| Q4 2024 | -12.6% | -15.0% | -23.5% | |
| Q3 2024 | -2.7% | -13.9% | -22.3% | |
| Q2 2024 | -8.8% | -12.5% | -10.6% | |
| Q1 2024 | +6.1% | +7.0% | -5.5% | |
| Q4 2023 | +10.0% | +8.5% | +11.9% | |
| Q3 2023 | -43.0% | -45.0% | -33.1% | |
| Q2 2023 | +5.3% | +11.2% | -0.5% | |
| Q1 2023 | +14.5% | +22.8% | +2.7% | |
| Q4 2022 | +1.2% | -2.1% | -9.1% | |
| Q3 2022 | -14.1% | -4.3% | -17.4% | |
| Q2 2022 | -0.1% | -7.3% | -8.1% | |
| Q1 2022 | -16.4% | -24.7% | +1.3% | |
| Q4 2021 | +7.6% | +5.7% | -3.2% | |
| Q3 2021 | +0.8% | -1.0% | -8.8% | |
| Q2 2021 | +4.9% | +7.1% | +39.0% | |
| Q1 2021 | -4.6% | -1.3% | -9.0% | |
| Q4 2020 | +1.4% | -0.7% | +45.7% | |
| Q3 2020 | -5.6% | -2.1% | +36.3% | |
| Q2 2020 | +1.0% | +7.2% | -10.6% | |
| Q1 2020 | +4.5% | +8.2% | +10.5% | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro